Scarica l'app Stockscreener
4.256
0.82%
-0.034
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARDX Giù?
Forum
Previsione
Precedente Chiudi:
$4.29
Aprire:
$4.29
Volume 24 ore:
2.60M
Relative Volume:
0.51
Capitalizzazione di mercato:
$1.02B
Reddito:
$251.85M
Utile/perdita netta:
$-72.58M
Rapporto P/E:
-13.58
EPS:
-0.3134
Flusso di cassa netto:
$-63.80M
1 W Prestazione:
-3.73%
1M Prestazione:
+15.31%
6M Prestazione:
-22.50%
1 anno Prestazione:
-24.29%
Intervallo 1D:
$4.245
$4.3984
Intervallo di 1 settimana:
$4.21
$4.475
Portata 52W:
$3.21
$7.18
Ardelyx Inc Stock (ARDX) Company Profile
Nome
Ardelyx Inc
Settore
Industria
Telefono
510-745-7047
Indirizzo
34175 ARDENWOOD BLVD., FREMONT, CA
Confronta ARDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.255 | 1.03B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.85 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.22 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.80 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.31 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.37 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-18 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-02 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Ripresa | Ladenburg Thalmann | Buy |
| 2025-03-04 | Iniziato | BTIG Research | Buy |
| 2024-11-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-18 | Iniziato | Raymond James | Strong Buy |
| 2023-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-25 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-11-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Downgrade | Jefferies | Buy → Hold |
| 2021-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-23 | Iniziato | Wedbush | Outperform |
| 2021-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Ripresa | Citigroup | Buy |
| 2020-02-18 | Ripresa | Jefferies | Buy |
| 2020-02-12 | Iniziato | Citigroup | Buy |
| 2020-02-10 | Iniziato | Cowen | Outperform |
| 2019-04-08 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-24 | Iniziato | Jefferies | Buy |
| 2018-03-19 | Ripresa | Leerink Partners | Outperform |
| 2017-11-29 | Reiterato | Citigroup | Buy |
| 2017-11-22 | Reiterato | Ladenburg Thalmann | Buy |
| 2017-10-17 | Ripresa | Leerink Partners | Outperform |
| 2016-03-31 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-03-09 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-03 | Iniziato | Citigroup | Buy |
Mostra tutto
Ardelyx Inc Borsa (ARDX) Ultime notizie
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline - sg.finance.yahoo.com
What is the dividend policy of Ardelyx Inc. stockMaximize returns with smart investment plans - jammulinksnews.com
How strong is Ardelyx Inc. company’s balance sheetAchieve rapid capital gains with smart investing - jammulinksnews.com
What is Ardelyx Inc. company’s growth strategyAchieve consistent profits with proven methods - jammulinksnews.com
How does Ardelyx Inc. compare to its industry peersFree High-Return Strategy Alerts - jammulinksnews.com
Should I hold or sell Ardelyx Inc. stock in 2025Capitalize on momentum-driven investment opportunities - jammulinksnews.com
How does Ardelyx Inc. generate profit in a changing economyMaximize gains with professional stock picks - jammulinksnews.com
What makes Ardelyx Inc. stock price move sharplyUnlock powerful trading signals for profits - jammulinksnews.com
Does Ardelyx Inc. stock perform well during market downturnsGain the edge with real-time market data - jammulinksnews.com
What catalysts could drive Ardelyx Inc. stock higher in 2025Find market-beating stocks for your portfolio - jammulinksnews.com
What are Ardelyx Inc. company’s key revenue driversConsistently profitable trades - jammulinksnews.com
How Ardelyx Inc. stock performs during market volatilityRisk Aware High Growth Picks - Metal.it
Is Ardelyx Inc. a good long term investmentPhenomenal investment performance - Autocar Professional
What analysts say about Ardelyx Inc. stockMassive portfolio appreciation - Autocar Professional
Ardelyx Inc. Stock Analysis and ForecastExceptional portfolio growth - Autocar Professional
Ardelyx (ARDX) Announced New data for IBSRELA - MSN
What drives Ardelyx Inc. stock priceFree Stock Market Trend Analysis - Autocar Professional
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), TG Therapeutics (TGTX) and Ardelyx (ARDX) - The Globe and Mail
Ardelyx, Inc.'s (NASDAQ:ARDX) Price Is Right But Growth Is Lacking After Shares Rocket 28% - 富途牛牛
11 Best American Penny Stocks to Buy According to Analysts - Insider Monkey
5 stocks with growth potential: SOUN, JBL, MNTN, ARDX, RCEL - Markets.com
Ardelyx Announces Q2 2025 Financial Results Conference Call - AInvest
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 - The Globe and Mail
Lobbying Update: $540,000 of ARDELYX INC. lobbying was just disclosed - Nasdaq
Ardelyx Inc Azioni (ARDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ardelyx Inc Azioni (ARDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MOTT DAVID M | Director |
Jun 09 '25 |
Buy |
3.69 |
200,000 |
737,260 |
2,696,871 |
| Williams Laura A | Chief Medical Officer |
May 20 '25 |
Sale |
4.08 |
6,421 |
26,207 |
402,583 |
| Renz Justin A | Chief Financial Officer |
May 20 '25 |
Sale |
4.08 |
7,218 |
29,460 |
416,089 |
| RAAB MICHAEL | President & CEO |
May 20 '25 |
Sale |
4.08 |
46,817 |
191,079 |
1,547,937 |
| Kelliher Mike | See Remarks |
May 20 '25 |
Sale |
4.08 |
14,522 |
59,270 |
282,158 |
| GRAMMER ELIZABETH A | See Remarks |
May 20 '25 |
Sale |
4.08 |
5,992 |
24,456 |
311,731 |
| Foster Eric Duane | Chief Commercial Officer |
May 20 '25 |
Sale |
4.08 |
2,507 |
10,232 |
316,806 |
| MOTT DAVID M | Director |
May 15 '25 |
Buy |
3.29 |
100,000 |
329,120 |
2,496,871 |
| MOTT DAVID M | Director |
May 02 '25 |
Buy |
4.22 |
381,377 |
1,610,936 |
2,396,871 |
| RAAB MICHAEL | President & CEO |
May 02 '25 |
Option Exercise |
0.99 |
20,833 |
20,625 |
1,636,420 |
0.94%
1.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):